Seala (VG101) / Bionovo - LARVOL DELTA

Unraveling the Immune Puzzle: Role of Immunomodulation in Alzheimer's Disease. (PubMed, J Neuroimmune Pharmacol) - "Preclinical studies of immunomodulatory agents, including salidroside, festidinol, astragalin, sulforaphane, BM-MSC, simvastatin, Ab-T1, hTREM2, and XENP345, demonstrate promising effects. Additionally, clinical investigations of drugs such as simufilam, AL002, TB006, VGL101, DNL919, XPro1595, astragalus, and IBC-Ab002 underscore the therapeutic potential of targeting immune pathways in AD. This review emphasizes how neuroinflammation, microglial activation, and peripheral immune responses contribute to disease progression. By exploring immunomodulatory mechanisms, the article sheds light on potential therapeutic targets that could help mitigate AD pathology which may pave the way for novel interventions preventing neurodegeneration in AD."

Journal • Review • Alzheimer's Disease • CNS Disorders • Immunology • Oncology • CTNNB1 • TNFA

Interim Results for Iluzanebart (VGL101) From IGNITE, the First Interventional Phase 2 Study in Patients With ALSP (EAN 2024) - P2 | "These interim clinical trial results of iluzanebart support its continued development as a potential disease- modifying therapy for ALSP and TREM2 agonism as a potential therapeutic approach for this neurodegenerative disorder."

Clinical • P2 data • CNS Disorders • Psychiatry • CSF1R

Percutaneous left atrial appendage closure with SeaLA device in non-valvular atrial fibrillation. (PubMed, Catheter Cardiovasc Interv) - "The LAAC with the SeaLA device demonstrates encouraging feasibility, safety, and efficacy outcomes."

Clinical • Journal • Atrial Fibrillation • Cardiovascular • Hematological Disorders • Ischemic stroke • Thrombosis

Interim Results on VGL101 from IGNITE: First Interventional Phase 2 Study in Patients with Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) (AAN 2024) - P2 | "No therapies are currently approved for ALSP, and disease-modifying therapies are a critical unmet need. These are the first clinical trial results of a potential disease-modifying therapy for ALSP and of TREM2 agonism as a therapeutic approach in a neurodegenerative disorder."

Clinical • P2 data • CNS Disorders • CSF1R • NEFL

VGL101: An Immunotherapy that Enhances Microglial Survival for Adult-onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia (ALSP) (AAN 2024) - "These findings demonstrate VGL101 is a potent and selective TREM2 agonistic antibody, align with the hypothesis that TREM2 activation can compensate for CSF1R dysfunction, and support continued clinical development of VGL101 for the treatment of patients with ALSP."

Clinical • IO biomarker • CNS Disorders • CSF1R

A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled,nSingle and Multiple Ascending Intravenous Dose Study tonAssess the Safety, Tolerability, Pharmacokinetics of VGL101 in HealthynAdults (ANZCTR) - P1 | N=30 | Completed | Sponsor: Vigil Neuroscience, Inc | Not yet recruiting ➔ Completed

Trial completion • CNS Disorders

Electrophysiological responses of the left atrial appendage during pulsed-field electrical isolation utilizing a novel device in a canine model. (PubMed, J Cardiovasc Electrophysiol) - "These results suggest that with proper device-tissue contact and pulse intensity, LAAEI can be achieved using this novel device without serious complications. The LAAp RT patterns observed in this study could inform and guide the adjustment of the ablation strategy."

Journal • Preclinical

A Phase 1, First-in-human, Randomized, Double-blind, Placebo-controlled, Single and Multiple Ascending Intravenous Dose Study of a novel TREM2 agonist (VGL101) in Healthy Volunteers (HVs) (AAN 2023) - "Conclusions VGL101 demonstrated a favorable safety, PK profile and confirmation of CNS target engagement in healthy volunteers. The Phase 1 data supports further clinical development of VGL101 in ALSP."

Clinical • P1 data • CNS Disorders • TREM2

VGL101 Rescues CSF1R Dysfunction in Human Microglia And Macrophages: Evaluation of In Vitro Trem2 Agonism in Models Of A CSF1R-Dependent Leukodystrophy (AAIC 2022) - No abstract available

Preclinical • CSF1R

Use of a Microbial Sealant to Reduce Surgical Site Infections. (clinicaltrials.gov) - P4; N=100; Completed; Sponsor: University of Southern California

New P4 trial • Biosimilar • Colorectal Cancer • Immunology • Oncology